Importantly, 9 out of the 20 AD patient samples, and 8 out of the 20 non-AD control samples had an AD biomarker profile of P-tau, T-tau and Aβ1-42, which did not fit with the clinical diagnosis (Supplementary Table 2). The gene discussed is MAPT; the disease is Alzheimer disease.